Assignee
GENFIT
FR·61 granted patents·37 pending applications·244 citations·filing 2001–2025
Top patents by PatentIndex Score
98 records- 0198US11857523B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted Jan 2, 2024·7 cites·9 claims
- 0298US11850223B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted Dec 26, 2023·7 cites·10 claims
- 0398US11331292B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2020·Granted May 17, 2022·13 cites·11 claims
- 0497US12295928B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted May 13, 2025·2 cites·26 claims
- 0597US12053445B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2021·Granted Aug 6, 2024·7 cites·11 claims
- 0696US12310935B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted May 27, 2025·1 cites·28 claims
- 0796US12303480B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted May 20, 2025·1 cites·15 claims
- 0896US12295927B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted May 13, 2025·1 cites·26 claims
- 0996US12290498B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted May 6, 2025·1 cites·14 claims
- 1096US12233038B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted Feb 25, 2025·1 cites·24 claims
- 1195US7566737B2Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredientsGENFIT·Filed 2006·Granted Jul 28, 2009·23 cites·9 claims
- 1294US11974997B2RORgamma modulators and uses thereofGENFIT·Filed 2021·Granted May 7, 2024·7 cites·14 claims
- 1393US12053456B2Pharmaceutical compositions for combination therapyGENFIT·Filed 2021·Granted Aug 6, 2024·3 cites·9 claims
- 1493US11185519B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2017·Granted Nov 30, 2021·15 cites·10 claims
- 1593US9221751B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2014·Granted Dec 29, 2015·9 cites·21 claims
- 1692US11590108B2Pharmaceutical compositions for combination therapyGENFIT·Filed 2018·Granted Feb 28, 2023·9 cites·8 claims
- 1791US11478440B2Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agentGENFIT·Filed 2018·Granted Oct 25, 2022·10 cites·3 claims
- 1891US9585853B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2015·Granted Mar 7, 2017·4 cites·15 claims
- 1990US9782373B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2017·Granted Oct 10, 2017·3 cites·6 claims
- 2088US10350181B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2018·Granted Jul 16, 2019·2 cites·19 claims
- 2186US11484517B2Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitorGENFIT·Filed 2018·Granted Nov 1, 2022·10 cites·2 claims
- 2286US10653678B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2018·Granted May 19, 2020·3 cites·6 claims
- 2386US8895619B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2014·Granted Nov 25, 2014·8 cites·11 claims
- 2486US2025281437A1Methods of treatment of cholestatic diseasesGENFIT·Filed 2025·Application pending·0 cites
- 2585US11052092B2N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseasesGENFIT·Filed 2018·Granted Jul 6, 2021·3 cites·16 claims
- 2685US11033534B2Pharmaceutical compositions for combination therapyGENFIT·Filed 2018·Granted Jun 15, 2021·3 cites·10 claims
- 2784US7547729B21,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of sameGENFIT·Filed 2005·Granted Jun 16, 2009·9 cites·6 claims
- 2883US7375135B2Fatty acid derivatives; preparation and uses thereofGENFIT·Filed 2002·Granted May 20, 2008·39 cites·43 claims
- 2982US11400078B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2020·Granted Aug 2, 2022·1 cites·6 claims
- 3080US10905680B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2018·Granted Feb 2, 2021·1 cites·18 claims
- 3179US12208087B2Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammationGENFIT·Filed 2020·Granted Jan 28, 2025·1 cites·10 claims
- 3279US7385082B2Preparation of 1,3-diphenylprop-2-en-1-one derivativesGENFIT·Filed 2004·Granted Jun 10, 2008·10 cites·15 claims
- 3378US10130613B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2017·Granted Nov 20, 2018·1 cites·10 claims
- 3478US10130612B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2017·Granted Nov 20, 2018·1 cites·11 claims
- 3578US10117856B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2017·Granted Nov 6, 2018·1 cites·10 claims
- 3678US10117855B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2017·Granted Nov 6, 2018·1 cites·14 claims
- 3778US9902725B2Heterocyclic derivatives as RORgamma modulatorsGENFIT·Filed 2015·Granted Feb 27, 2018·4 cites·19 claims
- 3876US7632870B2Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereofGENFIT·Filed 2003·Granted Dec 15, 2009·8 cites·11 claims
- 3974US7943661B2Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereofGENFIT·Filed 2003·Granted May 17, 2011·7 cites·17 claims
- 4074US2024410010A1Non-invasive diagnostic of non-alcoholic steatohepatitisGENFIT·Filed 2024·Application pending·0 cites
- 4173US11103484B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2020·Granted Aug 31, 2021·0 cites·8 claims
- 4272US11676269B2Automated pattern recognition and scoring method of histological imagesGENFIT·Filed 2018·Granted Jun 13, 2023·3 cites·10 claims
- 4372US11191749B2Pharmaceutical compositions for combination therapyGENFIT·Filed 2018·Granted Dec 7, 2021·1 cites·8 claims
- 4470US2025118449A1Systems and methods for patient classificationGENFIT·Filed 2023·Application pending·0 cites
- 4569US10022343B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2017·Granted Jul 17, 2018·0 cites·10 claims
- 4666US9115073B21,3-diphenylpropane derivatives, preparations and uses thereofGENFIT·Filed 2012·Granted Aug 25, 2015·2 cites·18 claims
- 4765US2019000813A1Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2018·Application pending·0 cites
- 4865US2022323422A1Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2022·Application pending·0 cites
- 4963US10792277B2Methods of treatment of fibrosis and cancersGENFIT·Filed 2017·Granted Oct 6, 2020·0 cites·23 claims
- 5061US7253296B2Acylated aminopropanediols and analogues and therapeutic uses thereofGENFIT·Filed 2004·Granted Aug 7, 2007·1 cites·33 claims
Showing the top 50 of 98 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when GENFIT files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →